Manuel A. Navia
Corporate Officer/Principal bei AdipoGenix, Inc.
Profil
Manuel A.
Navia is the founder of Althexis Co., Inc. (founded in 1997) and Altus Pharmaceuticals, Inc. (founded in 1992).
He held the title of President & Chief Executive Officer at Althexis Co., Inc. in 2001 and was a Director at Altus Pharmaceuticals, Inc. Dr. Navia's current job was as a Member-Advisory Board at AdipoGenix, Inc. since 2011.
Dr. Navia's former jobs include being a Vice President & Senior Scientist at Vertex Pharmaceuticals, Inc. from 1989 to 1997, and an Executive Vice President-Research at Essential Therapeutics, Inc. from 2001 to 2003.
He also served as an Executive-in-Residence at Oxford Bioscience Partners and as a Strategic Advisor at Access BridgeGap Ventures.
Dr. Navia's education includes a graduate and doctorate degree from The University of Chicago, and an undergraduate degree from New York University.
Aktive Positionen von Manuel A. Navia
| Unternehmen | Position | Beginn |
|---|---|---|
AdipoGenix, Inc.
 AdipoGenix, Inc. Pharmaceuticals: MajorHealth Technology AdipoGenix, Inc. develops molecular pharmaceutical products. It offers small molecule pharmaceuticals to treat obesity and its co-morbidities. The firm’s technology includes AdipoBASE, AdipoSCREEN, AdipoPATH and AdipoTARGET. The company was founded by Gerri Waloga, Barbara E. Corkey, Stephen R. Farmer, James A. Hamilton, James L. Kirkland, H. Jeff Leighton and Paul F. Pilch in 1997 and is headquartered in Boston, MA. | Corporate Officer/Principal | 23.05.2011 |
Ehemalige bekannte Positionen von Manuel A. Navia
| Unternehmen | Position | Ende |
|---|---|---|
Access BridgeGap Ventures
 Access BridgeGap Ventures Investment ManagersFinance Founded in 2011, Access BridgeGap Ventures is a venture capital firm located in Cambridge, Massachusetts. The firm is the life sciences venture capital investment arm of Access Industries, Inc. | Corporate Officer/Principal | 10.10.2013 |
Essential Therapeutics, Inc.
 Essential Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Essential Therapeutics, Inc. manufactures pharmaceutical goods for viral and fungal infections | Technik-/Wissenschafts-/F&E-Leiter | 01.03.2003 |
Althexis Co., Inc.
 Althexis Co., Inc. Miscellaneous Commercial ServicesCommercial Services Althexis Co., Inc. researches and develops drugs for the treatment of human diseases. The company is based in Waltham, MA. Mass. The company was founded by Manuel A. Navia, Paul J. Althexis Co. was acquired by Essential Therapeutics, Inc. on October 25, 2001 for $18.84 million. | Gründer | 01.01.2001 |
| VERTEX PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | 01.01.1997 |
Altus Pharmaceuticals, Inc.
 Altus Pharmaceuticals, Inc. BiotechnologyHealth Technology Altus Pharmaceuticals, Inc. develops therapeutic products for gastrointestinal and metabolic diseases. Its principal activity is protein crystallization which is used to develop therapeutic products for gastrointestinal and metabolic diseases. The company was founded in October 1992 and is headquartered in Waltham, MA. | Gründer | - |
Ausbildung von Manuel A. Navia
| The University of Chicago | Doctorate Degree |
| New York University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
| Private Unternehmen | 6 |
|---|---|
Oxford Bioscience Partners
 Oxford Bioscience Partners Investment ManagersFinance Oxford Bioscience Partners is an Independent Venture Capital firm founded in 1992 by Edmund Martin Olivier, Alan G. Walton and Cornelius T. Ryan. The firm is headquartered in Boston. | Finance |
Altus Pharmaceuticals, Inc.
Altus Pharmaceuticals, Inc. BiotechnologyHealth Technology Altus Pharmaceuticals, Inc. develops therapeutic products for gastrointestinal and metabolic diseases. Its principal activity is protein crystallization which is used to develop therapeutic products for gastrointestinal and metabolic diseases. The company was founded in October 1992 and is headquartered in Waltham, MA. | Health Technology |
AdipoGenix, Inc.
AdipoGenix, Inc. Pharmaceuticals: MajorHealth Technology AdipoGenix, Inc. develops molecular pharmaceutical products. It offers small molecule pharmaceuticals to treat obesity and its co-morbidities. The firm’s technology includes AdipoBASE, AdipoSCREEN, AdipoPATH and AdipoTARGET. The company was founded by Gerri Waloga, Barbara E. Corkey, Stephen R. Farmer, James A. Hamilton, James L. Kirkland, H. Jeff Leighton and Paul F. Pilch in 1997 and is headquartered in Boston, MA. | Health Technology |
Essential Therapeutics, Inc.
Essential Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Essential Therapeutics, Inc. manufactures pharmaceutical goods for viral and fungal infections | Health Technology |
Althexis Co., Inc.
Althexis Co., Inc. Miscellaneous Commercial ServicesCommercial Services Althexis Co., Inc. researches and develops drugs for the treatment of human diseases. The company is based in Waltham, MA. Mass. The company was founded by Manuel A. Navia, Paul J. Althexis Co. was acquired by Essential Therapeutics, Inc. on October 25, 2001 for $18.84 million. | Commercial Services |
Access BridgeGap Ventures
Access BridgeGap Ventures Investment ManagersFinance Founded in 2011, Access BridgeGap Ventures is a venture capital firm located in Cambridge, Massachusetts. The firm is the life sciences venture capital investment arm of Access Industries, Inc. | Finance |
